Cart summary

You have no items in your shopping cart.

Garenoxacin

SKU: orb1225793

Description

A quinolone antibiotic for the treatment of Gram-positive and Gram-negative bacterial infections.Bacterial Infection Approved.

Images & Validation

Key Properties

CAS Number194804-75-6
MW426.4127
Purity>98% (HPLC)
FormulaC23H20F2N2O4
SMILESO=C(C1=CN(C2CC2)C3=C(C=CC(C4=CC5=C([C@@H](C)NC5)C=C4)=C3OC(F)F)C1=O)O
TargetAntibacterial
Solubility10 mM in DMSO

Bioactivity

In Vivo
Garenoxacin (12.5-50 mg/kg; s. c. ; once) is highly effective against the wild-type strain and mutants harboring a single mutation in a mouse pneumonia model with S. pneumonia infection. Garenoxacin (10 and 30 mg/kg; p.o. ; once) reduces the viable cell counts in the lungs and significantly prolongs survival on experimental secondary pneumococcal pneumonia caused by S. pneumoniae D-979 in BALB/c female mice. Animal model: Swiss mice with S. pneumonia infection. Dosage: 12.5, 25 and 50 mg/kg. Administration: Subcutaneous injection, once. Result: Significantly improved the survival rate.
In Vitro
Garenoxacin (BMS284756) (0-8 days) inhibits mycoplasmas and ureaplasmas with MIC90s ≤0.25 μg/mL against tested strains. Garenoxacin (48 h) inhibits S. aureus wild type and mutants with MICs of 0.0128-4.0 μg/mL. Garenoxacin inhibits topoisomerase IV and gyrase from S. aureus with IC50s of 1.25 to 2.5 and 1.25 μg/mL, respectively. Garenoxacin has a low propensity for selective enrichment of fluoroquinolone-resistant mutants among ciprofloxacin-susceptible isolates of S. aureus.: Cell Viability Assay Cell line: M. pneumonia, M. fermentans, M. hominis and Ureaplasma spp. Concentration: Incubation time: 24 h for Ureaplasma spp., 48 h for M. hominis, 4 to 8 days for M. pneumonia Result: Showed inhibition with MIC90s of 0.031 μg/mL, ≤0.008 μg/mL, ≤0.008 μg/mL and 0.25 μg/mL against M. pneumonia, M. fermentans, M. hominis and Ureaplasma spp. strains, respectively.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

BMS284756 | BMS 284756 | BMS-284756 | Garenoxacin. tradename Geninax

Similar Products

  • Garenoxacin mesylate [orb1685437]

    223652-82-2

    522.52

    C24H24F2N2O7S

    100 mg, 25 mg, 50 mg
  • Garenoxacin (Standard) [orb3025507]

    194804-75-6

    426.41

    C23H20F2N2O4

    10 mg
  • Garenoxacin mesylate hydrate [orb1299491]

    99.90%

    223652-90-2

    540.53

    C23H20F2N2O4.CH4O3S.H2O

    100 mg, 1 ml x 10 mM (in DMSO), 2 mg, 5 mg, 10 mg, 25 mg, 50 mg
  • Garenoxacin [orb1685515]

    194804-75-6

    426.41

    C23H20F2N2O4

    5 mg, 10 mg, 25 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Garenoxacin (orb1225793)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

200 mg
500 mg
2 mg
$ 90.00
5 mg
$ 120.00
10 mg
$ 150.00
25 mg
$ 250.00
50 mg
$ 360.00
100 mg
$ 530.00